Cytosystems receives ISO 13485 accreditation 

Cytosystems takes another step closer to delivering its’ lead product, BladderLight®, to market. 

Cytosystems has received ISO 13485 accreditation for the “design, manufacture and distribution of non-invasive laboratory based diagnostic tests for genitourinary cancers”. 

BladderLight® is a non-invasive urine based diagnostic and risk stratification assay for bladder cancer.  Ultimately, BladderLight® will reduce the need for patients to undergo cystoscopy, the current standard of diagnosis and monitoring for post treatment of bladder cancer.  Cystoscopy is an invasive and unpleasant technique; BladderLight® will benefit the patient, healthcare system, and allow clinical staff to focus on managing patients with / or having a high risk of bladder cancer.